Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de zanidatamabe em combinação com quimioterapia mais ou menos tislelizumabe em pacientes com câncer gástrico e esofágico avançado ou metastático HER2-positivo (HERIZON-GEA-01)

19 de outubro de 2026 atualizado por: Jazz Pharmaceuticals

Um estudo randomizado, multicêntrico, de fase 3 de zanidatamab em combinação com quimioterapia com ou sem tislelizumab em indivíduos com adenocarcinoma gastroesofágico metastático ou localmente avançado irressecável HER2-positivo (GEA)

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

920

Estágio

  • Fase 3

Acesso expandido

Não está mais disponível fora do ensaio clínico. Consulte registro de acesso expandido.

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Hesse
      • Frankfurt am Main, Hesse, Alemanha, 60488
        • Institut für Klinisch-Onkologische Forschung
      • Buenos Aires, Argentina, C1181ACH
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, 1264
        • Hospital de Gastroenterología Dr Bonorino Udaondo
      • Buenos Aires, Argentina, C1012
        • Instituto de Investigaciones Metabólicas - IDIM
      • Córdoba, Argentina, X5000HXL
        • Fundación Centro de Medicina Nuclear y Molecular ER
      • Córdoba, Argentina, X5008HHW
        • Centro Médico Privado CEMAIC
      • Pergamino, Argentina, 2700
        • Centro de Investigación Pergamino S.A.
      • Viedma, Argentina, R8500ACE
        • Centro de Investigación Clínica - Clínica Viedma
      • Bedford Park, Austrália, 5042
        • Flinders Medical Centre
      • Heidelberg, Austrália, 3084
        • Austin Health
      • Liverpool, Austrália, 2170
        • Liverpool Hospital
      • Murdoch, Austrália, 6150
        • Fiona Stanley Hospital
      • Barretos, Brasil, 14784-400
        • Centro Integrado de Pesquisa - CIP
      • Barretos, Brasil, 14784-400
        • Fundação Pio XII Hospital de Câncer de Barretos
      • Belo Horizonte, Brasil, 30130-090
        • Cenantron - Centro Avancado de Tratamento Oncologico Ltda
      • Brasília, Brasil, 70840-901
        • Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho
      • Fortaleza, Brasil, 60430-230
        • Instituto Do Câncer Do Ceará ICC
      • Porto Alegre, Brasil, 90050-170
        • Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
      • Porto Alegre, Brasil, 90050-170
        • Irmandade Da Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasil, 91350-200
        • Hospital Nossa Senhora Da Conceição
      • Santo André, Brasil, 09060-650
        • Núcleo de Pesquisa Clínica da Rede São Camilo
      • Sorocaba, Brasil, 18030-075
        • Instituto de Oncologia de Sorocaba
      • São Paulo, Brasil, 01246-000
        • Instituto do Cancer do Estado de São Paulo ICESP
      • Bonheiden, Bélgica, 2820
        • Imelda VZW
      • Brussels, Bélgica, 1200
        • Cliniques Universitaires Saint-Luc
      • Ghent, Bélgica, 9000
        • UZ Gent
      • Leuven, Bélgica, 3000
        • UZ Leuven
      • Liège, Bélgica, 4000
        • CHU de Liège
      • Toronto, Canadá, M5G 2C1
        • Princess Margaret Cancer Centre
      • Providencia, Chile, 7500000
        • Centro de Estudios Clínicos SAGA SpA
      • Santiago, Chile, 7500000
        • Sociedad Oncovida S.A
      • Santiago, Chile, 8150513
        • Icegclinic
      • Santiago, Chile, 8330336
        • BIOCINETIC SpA
      • Temuco, Chile, 4810469
        • Sociedad de Investigaciones Medicas Limitada
    • Region Metropolitan
      • Santiago, Region Metropolitan, Chile, 8420383
        • Centro Internacional de Estudios Clinicos CIEC
    • Santiago Metropolitan
      • Providencia, Santiago Metropolitan, Chile, 7500000
        • Fundación Arturo López Pérez (FALP) - PPDS
      • Beijing, China, 100142
        • Beijing Cancer Hospital
      • Beijing, China, 100191
        • Peking University Third Hospital
      • Beijing, China, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
      • Beijing, China, 101199
        • Beijing Luhe Hospital, Capital Medical University
      • Beijing, China, 100020
        • Beijing Chao-Yang Hospital, Capital Medical University
      • Bengbu, China, 233004
        • The First Affiliated Hospital of Bengbu Medical College
      • Changsha, China, 410031
        • Hunan Cancer Hospital
      • Changzhi, China, 046099
        • Changzhi People's Hospital
      • Changzhou, China, 213004
        • Changzhou First People's Hospital
      • Chengdu, China, 610042
        • Sichuan Cancer Hospital & Institute
      • Fuzhou, China, 350014
        • Fujian Cancer Hospital
      • Fuzhou, China, 350005
        • The First Affiliated Hospital of Fujian Medical University
      • Guangzhou, China, 510655
        • The Sixth Affiliated Hospital of Sun Yat-sen University
      • Guangzhou, China, 510055
        • Guangdong Provincial People's Hospital
      • Haikou, China, 570311
        • Hainan General Hospital
      • Hangzhou, China, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
      • Hangzhou, China, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, China, 310003
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
      • Hangzhou, China, 310017
        • Second Affiliated Hospital of Zhejiang University School of Medicine
      • Harbin, China, 150081
        • Harbin Medical University Cancer Hospital
      • Hefei, China, 230601
        • The Second Affiliated Hospital of Anhui Medical University
      • Hefei, China, 230031
        • Anhui Provincial Cancer Hospital
      • Hohhot, China, 01000
        • Affiliated Hospital of Inner Mongolia Medical University
      • Jinan, China, 250013
        • Jinan Central Hospital
      • Jinan, China, 250000
        • Shandong Cancer Hospital
      • Kunming, China, 650118
        • Yunnan Cancer Hospital
      • Lanzhou, China, 730050
        • Gansu Cancer Hospital
      • Lanzhou, China, 730013
        • The First Hospital of Lanzhou University
      • Nanchang, China, 330052
        • The First Affiliated Hospital of Nanchang University
      • Nanjing, China, 210008
        • Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School
      • Qingdao, China, 266003
        • The Affiliated Hospital of Qingdao University
      • Shanghai, China, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, China, 200080
        • Shanghai General Hospital
      • Shanghai, China, 200032
        • Fudan University Affiliated Zhongshan Hospital
      • Shanghai, China, 200025
        • Ruijin hospital Shanghai Jiao Tong University School of Medicine
      • Shenyang, China, 110801
        • Liaoning Cancer Hospital & Institute
      • Shijiazhuang, China, 50011
        • The Fourth Hospital of Hebei Medical University
      • Tianjin, China, 300060
        • Tianjin Medical University Cancer Institute & Hospital
      • Tianjin, China, 300041
        • Tianjin Medical University General Hospital
      • Tonghua, China, 143099
        • The Tonghua Central Hospital
      • Weihai, China, 264200
        • Weihai Municipal Hospital
      • Wenzhou, China, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, China, 430079
        • Hubei Cancer Hospital
      • Wuhan, China, 430023
        • Union Hospital Tongji Medical College HuaZhong University of Science and Technology
      • Wuxi, China, 214062
        • Affiliated Hospital of Jiangnan University
      • Xi'an, China, 710061
        • First Affiliated Hospital of Xi 'an Jiaotong University
      • Xiamen, China, 361003
        • The First Affiliated Hospital of Xiamen University
      • Yangzhou, China, 225001
        • Northern Jiangsu People's Hospital
      • Zhengzhou, China, 450052
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, China, 450003
        • Henan Cancer Hospital
      • Ürümqi, China, 830026
        • Cancer Hospital affiliated to Xinjiang Medical University
      • Singapore, Cingapura, 258500
        • National Cancer Center Singapore
      • Anyang-si, Coréia do Sul, 14068
        • Hallym University Sacred Heart Hospital
      • Busan, Coréia do Sul, 49201
        • Dong-A University Hospital
      • Daegu, Coréia do Sul, 41404
        • Kyungpook National University Chilgok Hospital
      • Goyang-si, Coréia do Sul, 10408
        • National Cancer Center
      • Incheon, Coréia do Sul, 21565
        • Gachon University Gil Medical Center
      • Seongnam-si, Coréia do Sul, 13620
        • Seoul National University Bundang Hospital
      • Seongnam-si, Coréia do Sul, 13496
        • CHA Bundang Medical Center, CHA University
      • Seoul, Coréia do Sul, 03080
        • Seoul National University Hospital
      • Seoul, Coréia do Sul, 05505
        • Asan Medical Center
      • Seoul, Coréia do Sul, 06351
        • Samsung Medical Center
      • Seoul, Coréia do Sul, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Coréia do Sul, 02841
        • Korea University Anam Hospital
      • Seoul, Coréia do Sul, 08308
        • Korea University Guro Hospital
      • Seoul, Coréia do Sul, 03080
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul, Coréia do Sul, 03686
        • Severance Hospital Yonsei University Health System - PPDS
      • Seoul, Coréia do Sul, 06229
        • Gangnam Severance Hospital, Yonsei University Health System
      • Badalona, Espanha, 8915
        • Hospital Universitario Germans Trias i Pujol
      • Barcelona, Espanha, 08035
        • Hospital Universitario Vall d'Hebron - PPDS
      • Girona, Espanha, 17007
        • Hospital Universitari de Girona Dr Josep Trueta
      • L'Hospitalet de Llobregat, Espanha, 08908
        • Institut Català d'Oncologia (Hospital Duran y Reynals)
      • Madrid, Espanha, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, Espanha, 28046
        • Hospital Universitario La Paz - PPDS
      • Málaga, Espanha, 29010
        • Hospital Regional Universitario de Malaga - Hospital General
      • Salamanca, Espanha, 32911
        • Complejo Asistencial Universitario de Salamanca - H. Clinico
      • Santander, Espanha, 39008
        • Hospital Universitario Marques de Valdecilla
      • Seville, Espanha, 41009
        • Hospital Universitario Virgen Macarena
      • Zaragoza, Espanha, 50009
        • Hospital Universitario Miguel Servet
    • Barcelona
      • Sabadell, Barcelona, Espanha, 08208
        • Corporacio Sanitaria Parc Tauli
    • Navarre
      • Pamplona, Navarre, Espanha, 31008
        • Complejo Hospitalario de Navarra
      • Tallinn, Estônia, 13419
        • North Estonia Medical Centre Foundation
      • Avignon, França, 84000
        • Sainte-Catherine, Institut du Cancer Avignon Provence
      • Bordeaux, França, 33000
        • EDOG - Institut Bergonie - PPDS
      • Dijon, França, 21079
        • Universite de Bourgogne - Faculte de Medecine - IN
      • Grenoble, França, 38043
        • Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
      • Lyon, França, 69008
        • Centre Léon Berard
      • Nantes, França, 44805
        • EDOG Institut de Cancerologie de l'Ouest - PPDS
      • Poitiers, França, 86021
        • CHRU de Poitiers La Miletrie
      • Rennes, França, 35000
        • EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
      • Saint-Priest-en-Jarez, França, 42270
        • CHRU de Brest - Hopital Morvan
      • Toulouse, França, 69437
        • Hôpital de Rangueil
      • Villejuif, França, 94800
        • Hôpital Saint Antoine
    • Gironde
      • Pessac, Gironde, França, 33600
        • CHU de Bordeaux - Hopital Haut Leveque
      • Tbilisi, Geórgia, 0112
        • Research Institute of Clinical Medicine
      • Tbilisi, Geórgia, 6000
        • High Technology Hospital MedCenter Ltd
      • Athens, Grécia, 124 64
        • Attikon University General Hospital
      • Thessaloniki, Grécia, 552 36
        • Agios Loucas Clinic SA
      • Thessaloniki, Grécia, 54622
        • Bioclinic Thessaloniki Oncology Department
      • Thessaloniki, Grécia, 57001
        • Interbalkan Medical Center of Thessaloniki Oncology Department
      • Guatemala City, Guatemala, 01010
        • Clinica Medica Especializada CELAN
      • Guatemala City, Guatemala, 01015
        • Grupo Medico Angeles
      • Salcajá, Guatemala, 09002
        • Centro Medico Integral de Cancerologia CEMIC
      • Eindhoven, Holanda, 5623 EJ
        • Catharina Hospital
      • Leiden, Holanda, 2333 ZA
        • Leids Universitair Medisch Centrum
      • Tilburg, Holanda, 5042 AD
        • ETZ-Elisabeth
      • Dublin, Irlanda, 8
        • St James's Hospital
      • Bologna, Itália, 40138
        • Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
      • Candiolo, Itália, 10060
        • Fondazione del Piemonte per l'Oncologia (IRCCS)
      • Genova, Itália, 16132
        • Ospedale Policlinico San Martino
      • Meldola, Itália, 47014
        • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
      • Milan, Itália, 20132
        • Ospedale San Raffaele S.r.l. - PPDS
      • Milan, Itália, 20162
        • ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda
      • Milan, Itália, 20133
        • Istituto Nazionale Dei Tumori
      • Modena, Itália, 41124
        • Azienda Ospedaliero Universitaria Di Modena Policlinico
      • Reggio Emilia, Itália, 43100
        • Arcispedale Santa Maria Nuova
      • Rome, Itália, 00168
        • Fondazione Policlinico Universitario A Gemelli
      • Verona, Itália, 37134
        • Centro Ricerche Cliniche Di Verona
      • Vicenza, Itália, 36100
        • Azienda ULSS 8 "Berica" - Ospedale San Bortolo
      • Chūōku, Japão, 104-0045
        • National Cancer Center Hospital
      • Fukuoka, Japão, 811-1395
        • National Hospital Organization Kyushu Cancer Center
      • Ina, Japão, 362-0806
        • Saitama Cancer Center
      • Matsuyama, Japão, 791-0245
        • Shikoku Cancer Center
      • Osaka, Japão, 540-0008
        • Osaka International Cancer Institute
      • Tokyo, Japão, 135-8550
        • The Cancer Institute Hospital of Japanese Foundation For Cancer Research
      • Ōsaka-sayama, Japão, 589-0014
        • Kindai University Hospital
    • Chiba
      • Chiba, Chiba, Japão, 260-0801
        • Chiba Cancer Center
      • Kashiwa-shi, Chiba, Japão, 277-8577
        • National Cancer Center Hospital East
    • Gihu
      • Gifu, Gihu, Japão, 501-1112
        • Gifu University Hospital
    • Gunma
      • Ota-shi, Gunma, Japão, 373-8550
        • Gunma Prefectural Cancer Center
    • Hyôgo
      • Akashi-shi, Hyôgo, Japão, 673-8558
        • Hyogo Cancer Center
    • Ibaraki
      • Kasama-Shi, Ibaraki, Japão, 309-1793
        • Ibaraki Prefectural Central Hospital
    • Kagawa-ken
      • Kita-Gun Miki-Cho, Kagawa-ken, Japão, 761-0701
        • Kagawa University Hospital
    • Kanagawa
      • Yokohama-Shi Asahi-Ku, Kanagawa, Japão, 241-0815
        • Kanagawa Cancer Center
    • Kumamoto
      • Chuo-Ku, Kumamoto, Japão, 860-8556
        • Kumamoto University Hospital - Honjo-Kuhonji Campus A
    • Kyoto-shi
      • Sakyo-ku, Kyoto-shi, Japão, 606-8507
        • Kyoto University Hospital
    • Miyagi
      • Osaki-Shi, Miyagi, Japão, 989-6136
        • Osaki Citizen Hospital
    • Okayama-ken
      • Kurashiki-Shi, Okayama-ken, Japão, 710-0052
        • Kurashiki Central Hospital
    • Osaka
      • Suita-Shi, Osaka, Japão, 565-0871
        • Osaka University Hospital
      • Takatsuki-Shi, Osaka, Japão, 569-8686
        • Osaka Medical and Pharmaceutical University Hospital
    • Tokyo
      • Shinjuku-Ku, Tokyo, Japão, 160-8582
        • Keio University Hospital
      • George Town, Malásia, 10990
        • Hospital Pulau Pinang
      • Kuching, Malásia, 93586
        • Sarawak General Hospital
      • Putrajaya, Malásia, 62675
        • National Cancer Institute ( Institut Kanser Negara)
      • Mexico City, México, 03100
        • Health Pharma Professional Research S.A de C.V.
      • Monterrey, México, 64460
        • Hospital Universitario Dr. Jose Eleuterio González
      • Oaxaca City, México, 68020
        • Centro de Investigacion Clinica de Oaxaca
      • Lodz, Polônia, 93-513
        • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
      • Warsaw, Polônia, 02-034
        • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
      • Almada, Portugal, 2801-951
        • Hospital Garcia de Orta
      • Coimbra, Portugal, 3000-459
        • Centro Hospitalar E Universitário de Coimbra EPE
      • Guimarães, Portugal, 4830-044
        • Hospital Senhora da Oliveira - Guimaraes, E.P.E
      • Lisbon, Portugal, 1649-035
        • Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
      • Matosinhos Municipality, Portugal, 4454-509
        • Unidade Local de Saúde de Matosinhos SA
      • Porto, Portugal, 4200-072
        • Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
      • Porto, Portugal, 4099-001
        • Centro Hospitalar do Porto EPE
      • Bristol, Reino Unido, BS2 8ED
        • Bristol Haematology and Oncology Centre
      • Edinburgh, Reino Unido, EH4 2XU
        • Western General Hospital Edinburgh - PPDS
      • Leeds, Reino Unido, LS9 7TF
        • St James University Hospital
      • London, Reino Unido, SE1 9RT
        • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
      • London, Reino Unido, SW7 3RP
        • Royal Marsden Hospital - London
      • London, Reino Unido, SW7 3RP
        • Royal Marsden Hospital - Surrey
      • Peterborough, Reino Unido, PE3 9GZ
        • Edith Cavell Hospital
      • Sheffield, Reino Unido, S10 2SJ
        • Weston Park Cancer Centre
      • Bucharest, Romênia, 022328
        • Fundeni Clinical Institute
      • Cluj-Napoca, Romênia, 400015
        • Prof Dr I Chiricuta Institute of Oncology - PPDS
      • Cluj-Napoca, Romênia, 400641
        • Medisprof SRL
      • Craiova, Romênia, 200347
        • Oncology Center Sfantul Nectarie
      • Belgrade, Sérvia, 11070
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade, Sérvia, 11000
        • University Clinical Center of Serbia - PPDS
      • Kamenitz, Sérvia, 21204
        • Oncology Institute of Vojvodina
      • Niš, Sérvia, 18000
        • University Clinical Center Nis
      • Hat Yai, Tailândia, 90110
        • Songklanagarind Hospital
      • Khon Kaen, Tailândia, 40000
        • Srinagarind Hospital, Khon Kaen University
      • Lak Si, Tailândia, 10210
        • Chulaborn Hospital
      • Taichung, Taiwan, 404472
        • China Medical University Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Ankara, Turquia (Türkiye), 06230
        • Hacettepe Universitesi Kanser Enstitusu
      • Edirne, Turquia (Türkiye), 22030
        • Trakya University Medical Faculty
      • Izmir, Turquia (Türkiye), 35220
        • Dokuz Eylul Universitesi
      • Seyhan, Turquia (Türkiye), 01130
        • Acibadem Adana Hospital
      • Trabzon, Turquia (Türkiye), 61310
        • Medical Park Trabzon Yildizli
      • Yenimahalle, Turquia (Türkiye), 06200
        • Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital
      • Dnipropetrovsk, Ucrânia, 49102
        • Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council - PPDS
      • Pretoria, África do Sul, 0184
        • Wilgers Oncology Centre
      • Bhubaneswar, Índia, 751019
        • All India Institute of Medical Sciences, Bhubaneswar
      • Gūrgaon, Índia, 122003
        • Artemis Hospital
      • Hyderabad, Índia, 500004
        • MNJ Institute of Oncology and Regional Cancer Centre
      • New Delhi, Índia, 110076
        • Indraprastha Apollo Hospitals
      • Patna, Índia, 800014
        • Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
      • Vijayawada, Índia, 520002
        • HCG City Cancer Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
  • Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
  • Adequate organ function
  • Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)

Exclusion Criteria:

  • Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer > 5 years prior to initial diagnosis of GEA
  • Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
  • Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
  • Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
  • Known history of or ongoing leptomeningeal disease (LMD)
  • Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
  • Known active hepatitis
  • Any history of human immunodeficiency virus (HIV) infection
  • Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
  • QTc Fridericia (QTcF) > 470 ms
  • Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Arm A

Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)

Administered intravenously (IV)

Outros nomes:
  • Herceptin®

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Experimental: Arm B

Zanidatamab plus physician's choice of CAPOX or FP

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Administered IV

Outros nomes:
  • ZW25
  • JZP598
  • Ziihera®
Experimental: Arm C

Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP

Administered orally (PO bid)

Administered IV

Administered IV

Administered IV

Administered IV

Outros nomes:
  • ZW25
  • JZP598
  • Ziihera®

Administered IV

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Progression-free survival (PFS) by BICR
Prazo: Up to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Up to 2.5 years
Overall survival
Prazo: Up to 3.5 years

The time from randomization to death due to any cause

Up to 3.5 years

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Concentração sérica de zanidatamab e tislelizumab
Prazo: Até 2 anos
Até 2 anos
Confirmed objective response rate (ORR) by BICR
Prazo: Up to 2.5 years

Number of patients who achieved a best overall response of complete response (CR) or (PR) as determined per RECIST 1.1 as assessed by BICR

Up to 2.5 years
Duration of response (DOR) by BICR
Prazo: Up to 2.5 years

The time from the first objective response (CR or PR) per BICR to documented progressive disease per RECIST 1.1 as assessed by BICR or death from any cause

Up to 2.5 years
PFS per Investigator assessment
Prazo: Up to 2.5 years

The time from randomization to the date of documented disease progression (per RECIST 1.1) as assessed by Investigator or death from any cause

Up to 2.5 years
Confirmed ORR per Investigator assessment
Prazo: Up to 2.5 years

Number of patients who achieved a best overall response of CR or PR as determined per RECIST 1.1 as assessed by Investigator

Up to 2.5 years
DOR per Investigator assessment
Prazo: Up to 2.5 years

The time from the first objective response (CR or PR) per Investigator to documented progressive disease per RECIST 1.1 as assessed by Investigator or death from any cause

Up to 2.5 years
Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR
Prazo: Up to 2.5 years

The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause

Up to 2.5 years
Assessment of Contribution of Components based on Overall Survival
Prazo: Up to 3.5 years

The time from randomization to death due to any cause

Up to 3.5 years
Incidence of adverse events
Prazo: Up to 2 years

Number of subjects who experienced adverse events or serious adverse events

Up to 2 years
Incidence of clinical laboratory abnormalities
Prazo: Up to 2 years

Number of patients who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Up to 2 years
Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)
Prazo: Up to 2.5 years

Changes from baseline in the EORTC QLQ-C30 scores

Up to 2.5 years
HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)
Prazo: Up to 2.5 years

Changes from baseline in the EORTC QLQ-OG25 scores

Up to 2.5 years
HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire
Prazo: Up to 2.5 years

Changes from baseline in the EORTC EQ-5D-5L questionnaire scores

Up to 2.5 years
Incidence of anti-drug antibodies (ADAs)
Prazo: Up to 2 years

Number of patients who develop ADAs

Up to 2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

2 de dezembro de 2021

Conclusão Primária (Real)

15 de julho de 2026

Conclusão do estudo (Estimado)

30 de setembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

5 de novembro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de dezembro de 2021

Primeira postagem (Real)

9 de dezembro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

19 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ZWI-ZW25-301
  • 2021-000296-36 (Número EudraCT)
  • jRCT2061230026 (Identificador de registro: Japan Registry for Clinical Trials (jRCT))
  • 2023-510319-20-00 (Ctis)
  • 2023 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever